Table 4 Fever persistence during the first 3 days of therapy among participants febrile at enrollment.

From: Efficacy of artemether lumefantrine vs chloroquine for the treatment of Plasmodium Vivax infection in Pakistan

Follow-up period

CQ alone (n = 40)

AL alone (n = 45)

CQ in combination PQ (n = 30)

AL in combination with PQ (n = 40)

P value

Day 1

12.5% (5/40)

0% (0/45)

3.3% (1/30)

5.0% (2/40)

0.022

Day 2

2.5% (1/40)

0% (0/45)

0% (0/30)

2.5% (1/40)

0.563

Day 3

2.5% (1/40)

0% (0/45)

0% (0/30)

2.5% (1/40)

0.70

  1. Percentages are calculated among participants febrile at baseline within each treatment group (CQ, n = 40; AL, n = 45; CQ + PQ, n = 30; AL + PQ, n = 40). Fever status was recorded on Days 1, 2, and 3 after treatment initiation. P values compare fever presence across treatment groups at each day using Fisher’s exact test (two-sided).
  2. Abbreviations: CQ, chloroquine; AL, artemether–lumefantrine; PQ, primaquine.
Back to article page